PON1 and metabolic syndrome: In short, our findings show that a combined curcumin-aminoguanidine therapy prevent dyslipidemia, increase PON 1 activity, and normalize NOx levels in DM; this may constitute a potentially effective new strategy for the management of cardiovascular complications observed in DM.